Linked Life Data

16424933

Source:http://linkedlifedata.com/resource/pubmed/id/16424933

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-1-20
pubmed:abstractText
Randomized, placebo-controlled trials have shown that eszopiclone, a newly available nonbenzodiazepine hypnotic, effectively treats the symptoms of insomnia. Its pharmacokinetic and pharmacodynamic parameters are similar to those of the other currently available nonbenzodiazepine hypnotics (i.e., zolpidem and zaleplon). The unique quality of eszopiclone lies in its product labeling. It is not restricted to short-term use, unlike both zolpidem and zaleplon. Dosing of eszopiclone should begin at 2 mg for nonelderly patients and may be initiated at or increased to 3 mg if clinically indicated. The 3-mg nightly dose is more effective at sleep maintenance. Eszopiclone is well tolerated, with the main treatment-emergent side effects being unpleasant taste, headache, and dizziness. No studies comparing eszopiclone with nonpharmacologic insomnia treatments or other hypnotic agents, including zolpidem and zaleplon, are currently available.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Jan
pubmed:issn
0899-8280
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
54-9
pubmed:dateRevised
2009-11-18
pubmed:year
2006
pubmed:articleTitle
Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent.
pubmed:affiliation
Department of Pharmacy Services, Baylor University Medical Center, Dallas, Texas 75246, USA. BenBr@BaylorHealth.edu
pubmed:publicationType
Journal Article